Surgical and Minimally Invasive Interventions for LUTS/BPH: Highlights from 2006  Rowland Illing  European Urology Supplements  Volume 6, Issue 12, Pages 701-709 (July 2007) DOI: 10.1016/j.eursup.2007.04.003 Copyright © 2007 European Association of Urology Terms and Conditions

Fig. 1 Surgical treatment of lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH) with holmium laser enucleation (HoLEP) versus transurethral resection of the prostate (TURP) [20]. Improvements in total International Prostate Symptom Score (IPSS), quality of life (QoL), and maximum flow rate (Qmax) were comparable between both groups at 2 yr of follow-up. European Urology Supplements 2007 6, 701-709DOI: (10.1016/j.eursup.2007.04.003) Copyright © 2007 European Association of Urology Terms and Conditions

Fig. 2 The efficacy of transurethral microwave thermotherapy (TUMT) is sustained in the majority of patients with lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH) up to 8 yr [24]. European Urology Supplements 2007 6, 701-709DOI: (10.1016/j.eursup.2007.04.003) Copyright © 2007 European Association of Urology Terms and Conditions

Fig. 3 Outcomes of interactive voting on a representative case (for details, see text) show that transurethral resection of the prostate (TURP) and open prostatectomy (OP) were chosen by the majority of patients. Three promising relatively new minimally invasive interventions (photoselective laser vaporisation [PVP], transurethral needle ablation [TUNA], and transurethral microwave therapy [TUMT]) were equally favoured. European Urology Supplements 2007 6, 701-709DOI: (10.1016/j.eursup.2007.04.003) Copyright © 2007 European Association of Urology Terms and Conditions

Fig. 4 Outcomes of interactive voting on a representative case (for details, see text) show that >80% of the attendees indicated transurethral resection of the prostate/transurethral incision of the prostate (TURP/TUIP) or photoselective laser vaporisation (PVP) as appropriate treatment options. European Urology Supplements 2007 6, 701-709DOI: (10.1016/j.eursup.2007.04.003) Copyright © 2007 European Association of Urology Terms and Conditions

Fig. 5 Pharmacologic treatment of lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH) via transperineal injection of botulinum toxin A (BoNTA). Patients who were refractory to medical treatment were treated with either 100U (prostate size <30ml, n=21) or 200U (prostate size >30ml, n=20) [37]. Significant improvements from baseline (all p<0.05 vs. baseline) after 1 yr were demonstrated in International Prostate Symptom Score (IPSS) and maximum flow rate (Qmax). European Urology Supplements 2007 6, 701-709DOI: (10.1016/j.eursup.2007.04.003) Copyright © 2007 European Association of Urology Terms and Conditions